Mark Wenlock is a Group Leader at Cyprotex, overseeing the expansion and diversification of Physical Chemistry services. With a background in in silico ADMET research at AstraZeneca, Mark has extensive experience in predictive sciences, physical organic chemistry, and drug design. As a Director at InSilicoLynx, Mark focused on developing software for Medicinal Chemistry access to in-vivo exposure parameter estimates. With a PhD in Organic Chemistry from Cardiff University, Mark is a skilled scientist with expertise in aqueous solubility, hydrophobicity, pKa, and plasma protein binding.
This person is not in any offices